文献速递淋巴瘤造血干细胞移植与细胞治疗

嵌合抗原受体T细胞治疗后复发或难治性大B细胞淋巴瘤:当前挑战与治疗选择

Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
PubMed 文献 · Br J Haematol · 2023-01-29

本文综述了嵌合抗原受体T细胞(CAR-T)治疗失败后复发或难治性弥漫性大B细胞淋巴瘤(DLBCL)患者的当前挑战与治疗选择。文中汇总了双特异性抗体、抗体药物偶联物及下一代CAR-T等新型免疫疗法在此类患者中的数据,并提出了这些新药的理想序贯框架。

要点

  • CAR-T治疗可为化疗免疫治疗失败的复发或难治性DLBCL提供持久缓解。
  • CAR-T治疗后难治或复发的患者结局不佳,管理仍是挑战。
  • 双特异性抗体、抗体药物偶联物及下一代CAR-T等新疗法可能提供治疗途径。

核心结论

  • CAR-T治疗后复发或难治的DLBCL患者结局不佳,随着CAR-T治疗前移,亟需针对此类患者的临床试验。

研究设计与样本

  • 综述,汇总CAR-T治疗失败后使用双特异性抗体、抗体药物偶联物及下一代CAR-T等药物的现有数据。

主要发现

  • CAR-T治疗可为化疗免疫治疗失败的复发或难治性DLBCL提供持久缓解,但CAR-T后难治或复发者结局不佳。
  • 已提出多种CAR-T治疗失败的机制,但此类患者的管理仍是挑战。

临床怎么用

  • 作者提出这些新型药物在CAR-T治疗失败后的理想序贯框架。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR-T therapy have poor outcomes. Multiple mechanisms of CAR-T therapy failure have been proposed but management of these patients remains a challenge. As CAR-T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR-T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody-drug conjugates and next-generation CAR-T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR-T therapy and provide a framework for the ideal sequencing of these novel agents.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Del Toro-Mijares R, Oluwole O, Jayani RV, et al. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options. Br J Haematol. 2023. PMID: 36709623. doi:10.1111/bjh.18656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。